Skip to main content
Log in

Prognosis of impulse control disorders in Parkinson’s disease: a prospective controlled study

  • Original Communication
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Background

The long-term prognosis of impulsive compulsive disorders (ICD) remains poorly studied in Parkinson’s disease (PD).

Objective

Evaluating the natural history of ICD and its impact on PD symptoms including cognition and treatment adjustments.

Materials and methods

We assessed PD patients at baseline (BL) with (BL-ICD+) or without (BL-ICD-) ICD despite dopamine agonist (DA) exposure of > 300 mg levodopa-equivalent daily dose for > 12 months at baseline and after more than two years of follow-up. ICD were assessed using the Ardouin’s Scale of Behaviors in PD (ASBPD), cognition using the Mattis scale, and PD symptoms using the UPDRS score. Treatment adjustments, DA withdrawal-associated symptoms, and ICDs social consequences were recorded.

Results

149 patients were included (78 cases and 71 controls), mean duration of follow-up was 4.4 ± 1 years. At baseline, psychiatric disorders were more common among BL-ICD + (42.3 vs 12.3% among BL-ICD-, p < 0.01). At follow-up, 53.8% of BL-ICD + were not ICD-free while 21.1% of BL-ICD- had developed ICD. BL-ICD + more frequently experienced akinesia (21.8 vs 8.5%, p = 0.043) and rigidity worsening (11.5 vs 1.4%, p = 0.019) following therapeutic modifications. Decision to decrease > 50% DA doses (12.8 vs 1.4%, p = 0.019) or to withdraw DA (19.2 vs 5.6%, p = 0.025) was more frequently considered among BL-ICD+ . At follow-up, the prevalence of cognitive decline was lower among BL-ICD + (19.2 vs 37.1%, p = 0.025).

Conclusion

ICDs were associated with increased psychiatric burden at baseline and better cognitive prognosis. Most patients were still showing ICDs at the follow-up visit, suggesting ICD to be considered as a chronic, neuropsychiatric disorder.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

Data availability

The data that support the findings of this study are available from the corresponding author, upon reasonable request.

References

  1. Potenza MN, Voon V, Weintraub D (2007) Drug Insight: impulse control disorders and dopamine therapies in Parkinson’s disease. Nat Rev Neurol 3:664–672

    Article  CAS  Google Scholar 

  2. Weintraub D, Mamikonyan E (2019) Impulse control disorders in Parkinson’s disease. AJP 176:5–11

    Article  Google Scholar 

  3. Voon V, Napier TC, Frank MJ et al (2017) Impulse control disorders and levodopa-induced dyskinesias in Parkinson’s disease: an update. Lancet Neurol 16:238–250

    Article  PubMed  Google Scholar 

  4. Santangelo G, Barone P, Trojano L et al (2013) Pathological gambling in Parkinson’s disease. A comprehensive review. Parkinsonism Relat Disord 19:645–53

    Article  PubMed  Google Scholar 

  5. Nirenberg MJ, Waters C (2006) Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 21:524–529

    Article  PubMed  Google Scholar 

  6. Nakum S, Cavanna AE (2016) The prevalence and clinical characteristics of hypersexuality in patients with Parkinson’s disease following dopaminergic therapy: a systematic literature review. Parkinsonism Relat Disord 25:10–16

    Article  PubMed  Google Scholar 

  7. Weintraub D, Claassen DO (2017) Impulse Control and Related Disorders in Parkinson’s Disease. Int Rev Neurobiol 133:679–717

    Article  PubMed  Google Scholar 

  8. Faouzi J, Corvol J-C, Mariani L-L (2021) Impulse control disorders and related behaviors in Parkinson’s disease: risk factors, clinical and genetic aspects, and management. Curr Opin Neurol 34:547–555

    Article  CAS  PubMed  Google Scholar 

  9. Kelly MJ, Baig F, Hu MT-M et al (2020) Spectrum of impulse control behaviours in Parkinson’s disease: pathophysiology and management. J Neurol Neurosurg Psychiatry 91:703–11

    Article  PubMed  Google Scholar 

  10. Weintraub D, Koester J, Potenza MN et al (2010) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67:589–595

    Article  PubMed  Google Scholar 

  11. Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A et al (2014) Impulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry 85:840–844

    Article  PubMed  Google Scholar 

  12. Corvol J-C, Artaud F, Cormier-Dequaire F et al (2018) Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology 91:e189-201

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Siri C, Cilia R, Reali E et al (2015) Long-term cognitive follow-up of Parkinson’s disease patients with impulse control disorders. Mov Disord 30:696–704

    Article  PubMed  Google Scholar 

  14. Mamikonyan E, Siderowf AD, Duda JE et al (2008) Long-term follow-up of impulse control disorders in Parkinson’s disease. Mov Disord 23:75–80

    Article  PubMed  PubMed Central  Google Scholar 

  15. Bastiaens J, Dorfman BJ, Christos PJ et al (2013) Prospective cohort study of impulse control disorders in Parkinson’s disease. Mov Disord 28:327–333

    Article  PubMed  PubMed Central  Google Scholar 

  16. Averbeck BB, O’Sullivan SS, Djamshidian A (2014) Impulsive and compulsive behaviors in Parkinson’s disease. Annu Rev Clin Psychol 10:553–580

    Article  CAS  PubMed  Google Scholar 

  17. Cormier-Dequaire F, Bekadar S, Anheim M et al (2018) Suggestive association between OPRM1 and impulse control disorders in Parkinson’s disease. Mov Disord 33:1878–1886

    Article  CAS  PubMed  Google Scholar 

  18. Tomlinson CL, Stowe R, Patel S et al (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653

    Article  PubMed  Google Scholar 

  19. Goetz CG, Tilley BC, Shaftman SR et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23:2129–2170

    Article  PubMed  Google Scholar 

  20. Schmidt R, Freidl W, Fazekas F et al (1994) The Mattis dementia rating scale: normative data from 1,001 healthy volunteers. Neurology 44:964–964

    Article  CAS  PubMed  Google Scholar 

  21. Dubois B, Burn D, Goetz C et al (2007) Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord 22:2314–2324

    Article  PubMed  Google Scholar 

  22. Ardouin C, Chéreau I, Llorca P-M et al (2009) Assessment of hyper- and hypodopaminergic behaviors in Parkinson’s disease. Rev Neurol (Paris) 165:845–856

    Article  CAS  PubMed  Google Scholar 

  23. Weiss HD, Marsh L (2012) Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson disease. Neurol Clin Pract 2:267–274

    Article  PubMed  PubMed Central  Google Scholar 

  24. Nirenberg MJ (2013) Dopamine agonist withdrawal syndrome: implications for patient care. Drugs Aging 30:587–592

    Article  CAS  PubMed  Google Scholar 

  25. Grant JE, Odlaug BL, Chamberlain SR et al (2013) A proof of concept study of tolcapone for pathological gambling: relationships with COMT genotype and brain activation. Eur Neuropsychopharmacol 23:1587–1596

    Article  CAS  PubMed  Google Scholar 

  26. Kurtis MM, Rajah T, Delgado LF et al (2017) The effect of deep brain stimulation on the non-motor symptoms of Parkinson’s disease: a critical review of the current evidence. npj Parkinson’s Dis 3:1–12

    Google Scholar 

  27. deS Santin MN, Voulleminot P, Vrillon A et al (2021) Impact of subthalamic deep brain stimulation on impulse control disorders in Parkinson’s disease: a prospective study. Mov Disord. 36:750–7

    Article  CAS  PubMed  Google Scholar 

  28. Liang J, Groves M, Shanker VL (2015) Clozapine treatment for impulse control disorders in Parkinson’s disease patients: a case series. Mov Disord Clin Pract 2:283–285

    Article  PubMed  PubMed Central  Google Scholar 

  29. Béreau M, Van Waes V, Servant M et al (2023) Apathy in Parkinson’s disease: clinical patterns and neurobiological basis. Cells 12:1599

    Article  PubMed  PubMed Central  Google Scholar 

  30. Scott BM, Eisinger RS, Burns MR et al (2020) Co-occurrence of apathy and impulse control disorders in Parkinson disease. Neurology 95:e2769–e2780

    Article  PubMed  PubMed Central  Google Scholar 

  31. Sierra M, Carnicella S, Strafella AP et al (2015) Apathy and impulse control disorders: Yin & Yang of dopamine dependent behaviors. J Parkinsons Dis 5:625–636

    Article  CAS  PubMed  Google Scholar 

  32. Marín-Lahoz J, Sampedro F, Martinez-Horta S et al (2019) Depression as a risk factor for impulse control disorders in Parkinson disease. Ann Neurol 86:762–769

    Article  PubMed  Google Scholar 

  33. Aarsland D, Påhlhagen S, Ballard CG et al (2011) Depression in Parkinson disease–epidemiology, mechanisms and management. Nat Rev Neurol 8:35–47

    Article  PubMed  Google Scholar 

  34. Aracil-Bolaños I, Strafella AP (2016) Molecular imaging and neural networks in impulse control disorders in Parkinson’s disease. Parkinsonism Relat Disord 22(Suppl 1):S101-105

    Article  PubMed  Google Scholar 

  35. Cowen PJ (2008) Serotonin and depression: pathophysiological mechanism or marketing myth? Trends Pharmacol Sci 29:433–436

    Article  CAS  PubMed  Google Scholar 

  36. Kraemmer J, Smith K, Weintraub D et al (2016) Clinical-genetic model predicts incident impulse control disorders in Parkinson’s disease. J Neurol Neurosurg Psychiatry 87:1106–1111

    Article  PubMed  Google Scholar 

  37. Zhi Y, Yuan Y, Si Q et al (2019) The association between DRD3 Ser9Gly polymorphism and depression severity in Parkinson’s disease. Parkinson’s Dis 2019:e1642087

    Google Scholar 

  38. Peciña M, Karp JF, Mathew S et al (2019) Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches. Mol Psychiatry 24:576–587

    Article  PubMed  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

Authors

Contributions

TW: Conception, execution of the study, analysis of the data, writing of the first draft, and review of the manuscript. TG: Conception, execution of the study, and analysis of the data. SB: Execution of the study, review, and critique of the manuscript. ER: Execution of the study, review, and critique of the manuscript. LLM: Execution of the study, review, and critique of the manuscript. MV: Execution of the study, review, and critique of the manuscript. AMB: Execution of the study, review, and critique of the manuscript. DG: Execution of the study, review, and critique of the manuscript. NM: Execution of the study, review, and critique of the manuscript. AP: Execution of the study, review, and critique of the manuscript. OR: Execution of the study, review, and critique of the manuscript. CB-C: Execution of the study, review, and critique of the manuscript. FO: Execution of the study, review, and critique of the manuscript. CA: Execution of the study, review, and critique of the manuscript. PK: Execution of the study, review, and critique of the manuscript. AM: Execution of the study, review, and critique of the manuscript. ML: Execution of the study, review, and critique of the manuscript. JLH: Execution of the study, review, and critique of the manuscript. PK: Execution of the study, review, and critique of the manuscript. AC: Execution of the study, review, and critique of the manuscript. VF: Execution of the study, review, and critique of the manuscript. DM: Execution of the study, review, and critique of the manuscript. LD: Execution of the study, review, and critique of the manuscript. AK: Execution of the study, review, and critique of the manuscript. CT: Conception, execution of the study, review, and critique of the manuscript. NM: Conception, execution of the study, analysis of the data, review, and critique of the manuscript. MA: Conception, execution, organization of the study, analysis of the data, review, and critique of the manuscript.

Corresponding author

Correspondence to Thomas Wirth.

Ethics declarations

Conflicts of interest

T.W. received grants from the Revue Neurologique, the France Parkinson, the Fondation Planiol and the APTES organizations, honorarium from Abbvie, Ipsen and travels funding from LVL medical, Abbvie, and the Movement disorders society, E.R. received honorarium for speech from orkyn aguettant, elivie and for participating in an advisory board from allergan, research support from Merz-Pharma, Orkyn, Aguettant, Elivie, Ipsen, Allergan, Everpharma, Fondation Desmarest, AMADYS, ADCY5.org, Agence Nationale de la Recherche, Societé Française de Médecine Esthétique, Dystonia Medical Research Foundation. The rest of the authors declares no conflict of interest.

Supplementary Information

Below is the link to the electronic supplementary material.

415_2023_12170_MOESM1_ESM.docx

Supplementary file1 (DOCX 13 KB) Detailed comparisons of current and history of psychiatric disorders between cases and controls at baseline. *p value <0.05

Supplementary file2 (PDF 48 KB) Flowchart of the study and evolution of the patients’ status

415_2023_12170_MOESM3_ESM.pdf

Supplementary file3 (PDF 80 KB) Forest plot showing the outcome of logistic regression determining the factors associated with ICD resolution among patients showing ICD at baseline. LEDD: levodopa-equivalent daily doses, COMTI: catechol ortho-methyl transferase inhibitor OR: Odd Ratio, CI: Confidence Interval. Odd ratios are given with their confidence intervals and their respective p-values

415_2023_12170_MOESM4_ESM.docx

Supplementary file4 (DOCX 13 KB) Motor consequences following therapeutic modifications in the whole cohort. *p value <0.05

Supplementary file5 (DOCX 12 KB) Description of social consequences of ICD among patients showing ICD at baseline

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wirth, T., Goetsch, T., Corvol, JC. et al. Prognosis of impulse control disorders in Parkinson’s disease: a prospective controlled study. J Neurol 271, 2412–2422 (2024). https://doi.org/10.1007/s00415-023-12170-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-023-12170-7

Keywords

Navigation